by Lonza
Discoveries in technology, medicine, and nutrition are emerging with accelerating speed and improving our health and quality of life. Brought to you by Lonza, “A View On” podcast is a series of short conversations with industry leaders. Join us to discuss new trends that are impacting scientific research, drug discovery and business. The series of monthly conversations with pharma, biotech and nutrition leaders from across industry and academia covers a wide range of topics from 3D bioprinting to therapeutic cannabinoids. In under ten minutes, each podcast takes the audience on a rapid but deep dive into an exciting development that promises to profoundly change or even revolutionize healthcare.
Language
🇺🇲
Publishing Since
6/22/2020
Email Addresses
0 available
Phone Numbers
0 available
March 4, 2025
Explore a cutting-edge approach to acid reflux management! Learn how linaprazan glurate could provide longer-lasting relief than traditional PPIs, and why it matters for those living with chronic GERD.
January 30, 2025
Driving Innovation Through Collaboration: The Future of mRNA Therapies In this episode, we are joined by three experts—Christoph Hein (Fraunhofer IPK), Bernhard Bobusch (FDX Fluid Dynamix), and Sönke Stocker (Lonza)—to explore how advanced fluidics, encapsulation techniques, and a truly collaborative approach are paving the way for potential solid-tumor vaccines now in preclinical trials. When you think about mRNA-based vaccines, have you ever considered the complex route these microscopic instructions must travel to deliver their life-changing code? This journey, essential for the therapy’s success, lies at the core of pharmaceutical research—where the challenge is to maximize stability and “bioavailability” so that each dose effectively reaches its cellular target. By enclosing mRNA within lipid nanoparticles (LNPs) using sophisticated mixing technologies, scientists can create the next generation of therapies—tailored to each patient’s needs. From prophylactic vaccines to personalized cancer treatments for solid tumors, these breakthroughs promise not only more effective but also safer medical solutions. In this episode, we spotlight FDmiX®, a groundbreaking mixer platform that enables the precise production of LNPs, driving forward the possibility of new, life-saving vaccines in the fight against cancer. Curious to Know More? Join us in this conversation hosted by Martina Ribar Hestericová, featuring Fraunhofer IPK’s Christoph Hein, FDX Fluid Dynamix’s Bernhard Bobusch, and Lonza’s Sönke Stocker as they unveil how FDmiX® and mRNA encapsulation could revolutionize the development of solid-tumor vaccines and other cutting-edge therapies. KEY TERMS IN CONTEXT: In the world of mRNA therapeutics, a mixer refers to specialized devices—like FDmiX®—that rapidly and uniformly combine mRNA and lipid solutions. By generating precise fluid flows, these mixers ensure the formation of consistently sized lipid nanoparticles. This consistency is crucial for achieving stable formulations that protect mRNA until it reaches its target cells. Lipid nanoparticles (LNPs) are tiny, fat-based carriers engineered to encapsulate and shield mRNA from degradation. Once administered, LNPs help transport their therapeutic cargo across cell membranes, allowing the mRNA to enter cells and guide protein production. In this way, LNPs bridge the gap between laboratory-synthesized mRNA and its ability to function effectively inside the body. In vitro transcription is an enzymatic process used to create mRNA molecules outside of living cells. By copying a portion of DNA, researchers can produce custom strands of mRNA to encode specific therapeutic proteins. Once purified, these mRNA molecules are encapsulated in LNPs to be delivered into the patient’s cells, where the proteins are then synthesized in vivo. Microfluidics involves manipulating tiny volumes of liquid through microscale channels, enabling precise control of flow and mixing. In mRNA manufacturing, this technology is key to creating uniform lipid nanoparticles by blending mRNA and lipid solutions in a highly controlled manner. However, these laminar devices are limited in throughput. Even though microfluidics and fluidic mixers may sound similar, they are fundamentally different devices. Fluidic mixers are based on turbulent mixing by integrating specialized flow paths—such as the oscillating nozzle in the FDmiX®— mixing platforms are taken to the next level generating rapid, turbulence-based mixing, ensuring consistency and minimizing product loss across all production scales from small batches to large volumes without compromising quality. Ionizable lipids are specially designed molecules that alter their charge based on the surrounding pH. In mRNA encapsulation, these lipids help form stable LNPs in the bloodstream while promoting the release of mRNA payloads once inside cells. Their pH-sensitive nature is essential for balancing stability, delivery efficiency, and minimizing poten
December 4, 2024
Ronnie Wei, Head of Biologics Discovery and Development at ModeX Therapeutics, and Atul Mohindra, Head of R&D for Biologics at Lonza, explore the transformative power of antibody-based therapies in modern medicine.
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.
